GlassScriptPhysician profile
Anna C Watson
NPI 1154955755
$1,621.00
in general payments reported to CMS, 2019-2025
17 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $496 · 2023: $246 · 2024: $197 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $628.40 | 2021-2025 | Veozah, Myrbetriq, Xtandi |
| Endo Pharmaceuticals INC. | $331.81 | 2021-2022 | |
| Urovant Sciences INC | $180.50 | 2021-2022 | |
| Amgen INC. | $90.20 | 2021-2023 | Prolia |
| Janssen Biotech, INC. | $63.12 | 2024 | Erleada, Akeega |
| C. R. Bard, INC. & Subsidiaries | $58.13 | 2024-2025 | |
| Urogen Pharma, INC. | $44.92 | 2023-2024 | Jelmyto |
| Sumitomo Pharma America, INC. | $44.25 | 2023-2025 | Gemtesa |
| Progenics Pharmaceuticals, INC. | $25.25 | 2025 | |
| Myriad Genetic Laboratories, INC. | $24.31 | 2024 | Prolaris |
| Tolmar, INC. | $23.96 | 2023 | |
| Teleflex LLC | $20.54 | 2021 | |
| Pfizer INC. | $18.65 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.15 | 2021 | |
| Merck Sharp & Dohme LLC | $17.90 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2023 | |
| Allergan, INC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.